Wellington Management Group LLP Sells 11,425 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Wellington Management Group LLP decreased its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 1.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 786,312 shares of the company's stock after selling 11,425 shares during the quarter. Wellington Management Group LLP owned about 1.32% of Twist Bioscience worth $36,540,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in shares of Twist Bioscience in the 4th quarter valued at $58,000. Westwood Holdings Group Inc. purchased a new position in shares of Twist Bioscience in the 4th quarter worth about $657,000. Teza Capital Management LLC purchased a new position in shares of Twist Bioscience in the 4th quarter worth about $204,000. Sherbrooke Park Advisers LLC purchased a new position in shares of Twist Bioscience in the 4th quarter worth about $238,000. Finally, ProShare Advisors LLC boosted its holdings in shares of Twist Bioscience by 30.5% in the 4th quarter. ProShare Advisors LLC now owns 19,226 shares of the company's stock worth $893,000 after buying an additional 4,488 shares during the last quarter.

Wall Street Analyst Weigh In

TWST has been the topic of several recent research reports. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Robert W. Baird lowered their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Guggenheim reissued a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, May 6th. Barclays decreased their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Finally, The Goldman Sachs Group decreased their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $50.40.

Twist Bioscience Stock Down 0.8%

Shares of TWST stock traded down $0.24 during mid-day trading on Wednesday, reaching $30.64. 320,370 shares of the company's stock traded hands, compared to its average volume of 981,413. Twist Bioscience Co. has a 12 month low of $27.12 and a 12 month high of $60.90. The company has a market cap of $1.84 billion, a P/E ratio of -9.07 and a beta of 2.54. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The company's 50-day moving average price is $34.85 and its 200-day moving average price is $42.17.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The company had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. On average, equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In other news, CFO Adam Laponis sold 936 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $27,846.00. Following the completion of the sale, the chief financial officer now owns 106,018 shares of the company's stock, valued at $3,154,035.50. This represents a 0.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Patrick John Finn sold 1,877 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $55,840.75. Following the transaction, the chief operating officer now owns 240,783 shares of the company's stock, valued at approximately $7,163,294.25. This trade represents a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,850 shares of company stock valued at $974,764 in the last quarter. 3.01% of the stock is owned by insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.